NewAmsterdam Pharma Co N.V. NAMS
We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol ("LDL-C") lowering therapy. In multiple Phase 3 trials, we have investigated obicetrapib, an oral, low-dose, once-daily, highly selective cholesteryl ester transfer protein ("CETP") inhibitor, alone or as a fixed-dose combination ("FDC") with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of cardiovascular disease ("CVD") with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Additionally, we believe that CETP inhibition may also play a role in other indications by potentially mitigating the risk of developing diseases such as Alzheimer's disease.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M | — | — |
| R&D | $141.8M | $151.4M | $159.4M | $86.7M | $29.0M | — |
| SG&A | $106.4M | $70.4M | $37.6M | $19.5M | $6.0M | — |
| Total operating expenses | $248.2M | $221.9M | $197.1M | $106.3M | $35.0M | — |
| Operating income | -$225.7M | -$176.3M | -$183.0M | -$3.6M | -$35.0M | — |
| Interest expense | — | — | — | $287.0K | $411.0K | — |
| Pre-tax income | -$203.8M | -$241.6M | -$176.9M | -$22.6M | -$41.8M | — |
| Income tax | — | $1.0K | $27.0K | — | — | — |
| Net income | -$203.0M | -$242.0M | -$177.0M | -$22.6M | -$41.8M | — |
| EPS, basic | -1.72 | -2.56 | -2.15 | -1.19 | -3.81 | — |
| EPS, diluted | -1.72 | -2.56 | -2.15 | -1.19 | -3.81 | — |
| Shares, diluted (wtd. avg.) | 118.4M | 94.4M | 82.2M | 19.0M | 11.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $490.0M | $771.7M | $340.4M | — | — | — |
| Short-term investments | $146.2M | $62.4M | — | — | — | — |
| Total current assets | $675.7M | $863.4M | $346.8M | $478.0M | — | — |
| Property, plant and equipment | $383.0K | $242.0K | $46.0K | $34.0K | — | — |
| Total assets | $769.3M | $864.6M | $347.1M | $478.5M | — | — |
| Accounts payable | $9.0M | $4.7M | $16.9M | $11.9M | — | — |
| Total current liabilities | $85.8M | $106.9M | $49.9M | $36.1M | — | — |
| Total liabilities | $85.9M | $107.1M | $58.7M | $48.4M | — | — |
| Retained earnings | -$762.4M | -$558.6M | -$317.0M | -$140.0M | — | — |
| Total equity | $683.4M | $757.5M | $288.4M | $430.1M | -$113.8M | -$73.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$147.8M | -$158.6M | -$141.2M | $10.7M | -$29.5M | — |
| Depreciation and amortisation | $220.0K | $113.0K | $49.0K | $9.0K | $5.0K | — |
| Stock-based compensation | $59.4M | $33.6M | $24.6M | $4.1M | $1.2M | — |
| Capital expenditure | $246.0K | $672.0K | $24.0K | $221.0K | $24.0K | — |
| Investing cash flow | -$174.9M | -$62.8M | -$24.0K | -$221.0K | -$24.0K | — |
| Financing cash flow | $29.5M | $659.5M | $8.9M | $391.9M | $84.7M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-207562.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $102.7M | $14.1M | $45.6M | $22.5M |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$41.8M | -$22.6M | -$177.0M | -$242.0M | -$203.0M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Officer or director change Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |